Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-04 8:33 pm Purchase | 13D | Q32 BIO INC QTTB | ACORN BIOVENTURES L.P. | 803,425 6.7% | 803,425 (New Position) | View |
| 2024-02-14 4:44 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | ACORN BIOVENTURES L.P. | 17,755,869 9.99% | 17,755,869 (New Position) | View |
| 2024-02-13 5:16 pm Purchase | 13G | OPTINOSE INC OPTN | ACORN BIOVENTURES L.P. | 12,042,008 9.9% | 673,050 (+5.92%) | View |
| 2024-02-07 5:03 pm Sale | 13G | CYCLACEL PHARMACEUTICALS INC CYCC | ACORN BIOVENTURES L.P. | 0 0% | -2,815,146 (Position Closed) | View |
| 2024-02-06 4:01 pm Sale | 13G | CARDIFF ONCOLOGY INC CRDF | ACORN BIOVENTURES L.P. | 1,946,762 4.2% | -1,096,411 (-36.03%) | View |
| 2024-02-06 3:59 pm Purchase | 13G | Y-MABS THERAPEUTICS INC YMAB | ACORN BIOVENTURES L.P. | 2,761,825 6.3% | 435,297 (+18.71%) | View |
| 2024-02-06 3:57 pm Purchase | 13G | BIOATLA INC BCAB | ACORN BIOVENTURES L.P. | 4,032,046 8.4% | 1,305,591 (+47.89%) | View |
| 2024-02-06 3:54 pm Purchase | 13G | PUMA BIOTECHNOLOGY INC PBYI | ACORN BIOVENTURES L.P. | 2,934,496 6.2% | 194,561 (+7.10%) | View |
| 2023-09-01 10:18 am Purchase | 13G | PUMA BIOTECHNOLOGY INC PBYI | ACORN BIOVENTURES L.P. | 2,739,935 5.8% | 2,739,935 (New Position) | View |
| 2023-04-27 12:11 pm Purchase | 13G | BIOATLA INC BCAB | ACORN BIOVENTURES L.P. | 2,726,455 5.7% | 2,726,455 (New Position) | View |
| 2023-04-03 1:46 pm Purchase | 13G | Y-MABS THERAPEUTICS INC YMAB | ACORN BIOVENTURES L.P. | 2,326,528 5.3% | 2,326,528 (New Position) | View |
| 2023-01-26 1:36 pm Purchase | 13G | CYCLACEL PHARMACEUTICALS INC CYCC | ACORN BIOVENTURES L.P. | 2,815,146 9.99% | 470,655 (+20.07%) | View |
| 2023-01-26 1:30 pm Unchanged | 13G | CARDIFF ONCOLOGY INC CRDF | ACORN BIOVENTURES L.P. | 3,043,173 6.38% | 0 (Unchanged) | View |
| 2023-01-26 1:28 pm Sale | 13D | CARDIFF ONCOLOGY INC CRDF | ACORN BIOVENTURES L.P. | 3,043,173 6.38% | -2,947,666 (-49.20%) | View |
| 2022-12-05 4:30 pm Purchase | 13G | OPTINOSE INC OPTN | ACORN BIOVENTURES L.P. | 11,368,958 9.9% | 11,368,958 (New Position) | View |
| 2021-02-12 4:58 pm Purchase | 13G | CYCLACEL PHARMACEUTICALS INC CYCC | ACORN BIOVENTURES L.P. | 2,344,491 9.99% | 2,344,491 (New Position) | View |
| 2020-07-02 2:59 pm Purchase | 13D | CARDIFF ONCOLOGY INC CRDF | ACORN BIOVENTURES L.P. | 5,990,839 9.99% | 4,303,279 (+255.00%) | View |
| 2020-06-04 4:14 pm Purchase | 13G | CARDIFF ONCOLOGY INC CRDF | ACORN BIOVENTURES L.P. | 1,687,560 9.99% | 1,687,560 (New Position) | View |